Linked Life Data

8281620

Source:http://linkedlifedata.com/resource/pubmed/id/8281620

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
1994-2-17
pubmed:abstractText
Studies are described in which a new folate analogue, edatrexate (EDX), in combination with the vinca alkaloids, vinblastine (VBL), navelbine (NVB) or vindesine (DVA) was evaluated against E0771 mammary adenocarcinoma, T241 fibrosarcoma and the Lewis lung tumor. Each of the four agents when given individually to animals 3 days after transplant of these tumors resulted in increases in survival of 53-143%. The relative effectiveness of these agents was (in increasing order) VBL, NVB congruent to DVA, EDX, with no long-term survivors obtained with any. Combination therapy with EDX and vinca alkaloids required dosage attenuation but was still markedly more effective. Treatment of E0771 and T241 tumors with EDX and either NVB or DVA increased survival 3- to 4-fold compared with therapy with individual agents and yielded 40-70% long-term survivors, while EDX with VBL increased survival 2- to 3-fold and yielded 20-40% long-term survivors. Simultaneous or sequential (EDX given 24 h before vinca alkaloid) administration of combined therapy was equally effective. Sequential administration of these agents at the same doses in the reverse order was highly toxic and required further dosage attenuation which compromised efficacy. Effects of these combinations against the Lewis Lung tumor were not as pronounced and were somewhat schedule-dependent. Simultaneous administration of EDX with VBL, NVB or DVA increased survival 2- to 3-fold over that obtained with single agents alone and yielded 10-40% long-term survivors, while sequential administration increased survival < 2-fold over that obtained with single agents and yielded 0-20% long-term survivors. These results suggest that combined therapy with these agents in patients may have appreciable utility and provide a basis for further clinical trials.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0344-5704
pubmed:author
pubmed:issnType
Print
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
286-90
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1994
pubmed:articleTitle
Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine.
pubmed:affiliation
Program in Molecular Pharmacology and Therapeutics Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't